This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
WCBP 2018: Roundtable Information
Share |

 

Roundtable Session 1: Tuesday, January 30, 15:45 - 16:45

 

Spotlight Topic: From PPQ Batches to Product Licensure - Continuous Process Improvement
FACILITATORS: John Eschelbach, Genentech, a Member of the Roche Group and Bryan SilveyKite Pharma, Inc 
SCRIBES: Bharat Dixit, Finch Therapeutics Group and Bob Kuhn, Amgen Inc.

To view the table abstract and discussion notes, click here.

 

Table 1: Evolution of CQAs Throughout a Program Lifecycle
FACILITATOR: Nomalie Jaya, Seattle Genetics, Inc.
SCRIBE: John Kim, Teva Pharmaceuticals

To view the table abstract and discussion notes, click here.

 

Table 2: New Mechanisms for DS Process Control
FACILITATOR: Carmilia Jimenez Ramirez, Gilead Sciences Inc.
SCRIBE: Mandy Xie, GlaxoSmithKline

To view the table abstract and discussion notes, click here.

 

Table 3:  Visible Particles: Just Another Critical Quality Attribute
FACILITATOR: Roman Drews, Daiichi Sankyo, Inc.
SCRIBE: Zahra Shahrokh, STC Biologics

To view the table abstract and discussion notes, click here.

 

Table 4: PAI Inspections (including Mutual Inspection Experiences)
FACILITATOR: Cynthia Ball, MedImmune, A member of AstraZeneca Group
SCRIBE: Namita Nayak, BioMarin Pharmaceutical Inc.

To view the table abstract and discussion notes, click here.

 

Table 5: Replacing in vivo with in vitro Potency Assays
FACILITATOR: Barbara Capecchi, GlaxoSmithKline
SCRIBE: Todd Ranheim, Takeda Pharmaceutical Company Limited

To view the table abstract and discussion notes, click here.

 

Table 6: Immunogenicity and Regulator's Current Expectations
FACILITATOR: Taro Fujimori, AbbVie Inc.
SCRIBE: Fadi Hakki, MedImmune, A member of the AstraZeneca Group

To view the table abstract and discussion notes, click here.

 

Table 7: QbD Implementation: Learning from the Past to Shape the Future
FACILITATOR: Christof Finkler, F. Hoffmann - La Roche Ltd.
SCRIBE: Min Du, Waters Corporation

To view the table abstract and discussion notes, click here.

 

Table 8: Biosimilarity Assessment
FACILITATOR: Emily Shacter, ThinkFDA LLC
SCRIBE: Chris Chumsae, Abbvie Inc.

To view the table abstract and discussion notes, click here.

 

Table 9: Lifecycle Considerations for Bridging Analytical Methods
FACILITATOR: Ken Miller, AstraZeneca
SCRIBE: Eric Pastor, Sanofi

To view the table abstract and discussion notes, click here.

 

Table 10: ADCs: mAb or DS for Characterization and Control 
FACILITATOR: Scott Henry, Seattle Genetics, Inc
SCRIBE: Jolie Ziemba, Pfizer, Inc.

To view the table abstract and discussion notes, click here.

 

Table 11: Frozen Stability: To Test or Not to Test, A New DS Stability Paradigm?
FACILITATOR: Cleo Salisbury, Genentech, a Member of the Roche Group
SCRIBE: Anders Dybdal Nielsen, Novo Nordisk A/S

To view the table abstract and discussion notes, click here.

 

Table 12: Design of Stability Studies for Biotechnology Product Development and Lifecycle Management – A New USP Chapter 
FACILITATOR: Joseph Kutza, MedImmune, A member of the AstraZeneca Group
SCRIBE: Camilla Santos, Amgen Inc.

To view the table abstract and discussion notes, click here.

 

Table 13: Early Specs for Tox and FIH
FACILITATOR: Cristiana Campa, GlaxoSmithKline
SCRIBE: Kris Antonsen, BioMarin Pharmaceutical Inc.

To view the table abstract and discussion notes, click here.

 

Table 14: In-country Manufacturing to Enable Lower Cost Medicines in Developing Countries
FACILITATOR: John Amery, Pfizer, Inc.
SCRIBE: Stephanie Ranck, Eli Lilly and Company

To view the table abstract and discussion notes, click here.

 

Table 15: Lifecycle Management: Risk Assessments
FACILITATOR: Tom Monica, Amgen Inc.
SCRIBE: Kate Schembri, Genentech, a Member of the Roche Group

To view the table abstract and discussion notes, click here.

 

Table 16: Control Strategies IPCs/PAT
FACILITATOR: Taylor Zhang, Genentech, a Member of the Roche Group
SCRIBE: Carol Krantz, Seattle Genetics, Inc.

To view the table abstract, click here.

 

Table 17: Shipping Qualification
FACILITATOR: Edwin Moore, BioPhia Consulting, Inc.
SCRIBE: Rob McCombie, Genentech, a Member of the Roche Group

To view the table abstract and discussion notes, click here.

 

Table 18: Characterization Assays for Early Product Development
FACILITATOR: Joe Siemiatkoski, J Siemiatkoski Consulting
SCRIBE: Kathy Lee, Eli Lilly and Company

To view the table abstract, click here.

 

Table 19: Quality or Regulatory Submission: New Items in  Regulatory Filings?
FACILITATOR: Jennifer Mercer, BioMarin Pharmaceutical Inc.
SCRIBE: Uma Balasubramanian, Daiichi Sankyo. Co., Ltd.

To view the table abstract and discussion notes, click here.

 

Table 20: Glycan Comparability Between Processes
FACILITATOR: Dietmar Reusch, F. Hoffmann - La Roche Ltd.
SCRIBE: Nicole Piros, Genentech, a Member of the Roche Group

To view the table abstract and discussion notes, click here.

 

Table 21: Phase Appropriate Control Strategy for Host Cell Protein
FACILITATOR: Markus Haindl, F. Hoffmann - La Roche Ltd.
SCRIBE: James Carroll, Pfizer, Inc.

To view the table abstract and discussion notes, click here.

 

Table 22: Forced Degradation
FACILITATOR: Tanya Shang, Pfizer, Inc
SCRIBE: Cari Sänger – van de Griend, Kantisto BV

To view the table abstract and discussion notes, click here.

 

Table 23: Surfactants: Control, Use , and Characterization
FACILITATOR: Kunal Bakshi, GlaxoSmithKline
SCRIBE: Huan Wang, Teva Pharmaceuticals

To view the table abstract and discussion notes, click here.

 

Table 24: Rare Disease-specific and Expedited Review Regulations in Emerging Markets
FACILITATOR: Nina Cauchon, Amgen Inc.
SCRIBE: Santosh Yadev, Merck & Co, Inc.

To view the table abstract and discussion notesclick here.

 

Table 25: Pool for Tox…Pool for Ph1 GMP?
FACILITATOR: Patsy Lewis, Seattle Genetics, Inc.
SCRIBE: JR Dobbins, Eli Lilly and Company

To view the table abstract and discussion notes, click here.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Roundtable Session 2: Wednesday, January 31, 12:15 - 13:15




Spotlight Topic: Reference Standard: Common Practices and Challenges

FACILITATORS: Zahra Shahrohk, STC Biologics and Qiang Qin, MedImmune, A member of the AstraZeneca Group
SCRIBES: Tami Wu, Seattle Genetics, Inc. and John Kim, Teva Pharmaceuticals

To view the table abstract and discussion notes, click here.

    
Table 26: Evolution of CQAs Throughout a Program Lifecycle
FACILITATOR: Armando Cordoba, Genentech, a Member of the Roche Group
SCRIBE: Kirby Steger, Johnson & Johnson

To view the table abstract and discussion notes, click here.

 

Table 27: Patient Centric Drug Development
FACILITATOR: Trent Munro, Amgen Inc.
SCRIBE: Cari Sänger – van de Griend, Kantisto BV

To view the table abstract and discussion notes, click here.

 

Table 28: Visible Particles: Just Another Critical Quality Attribute
FACILITATOR: Jan Stracke, F. Hoffmann-La Roche Ltd.
SCRIBE: Linda Wilbur, BioMarin Pharmaceutical Inc.

To view the table abstract and discussion notes, click here.

 

Table 29: PAI Inspections (including Mutual Inspection Experiences)
FACILITATOR: Richard Keane, Biogen
SCRIBE: Sianna Castillo, BioMarin Pharmaceutical Inc.

To view the table abstract and discussion notes, click here. 

 

Table 30: ID Testing from Start to Finish, Technical Approaches and Regulatory Requirements
FACILITATOR: Allison Torgesen, Seattle Genetics, Inc.
SCRIBE: Anissa Irwin, Genentech, a Member of the Roche Group

To view the table abstract and discussion notes, click here.

 

Table 31: Immunogenicity and Regulator's Current Expectations
FACILITATOR: Victor Lundin, Genentech, a Member of the Roche Group
SCRIBE: Nicholas Manzo, GlaxoSmithKline

To view the table abstract and discussion notes, click here.

 

Table 32: Surfactants: Control, Use , and Characterization
FACILITATOR: Jason Starkey, Pfizer, Inc.
SCRIBE: Edwin Moore, BioPhia Consulting, Inc.

To view the table abstract and discussion notes, click here.

 

Table 33: In-country Manufacturing to Enable Lower Cost Medicines in Developing Countries
FACILITATOR: Darrin Cowley, Amgen Inc.
SCRIBE: Joseph Siemiatkoski, J Siemiatkoski Consulting

To view the table abstract, click here.

 

Table 34: Validation of Release Assay for Aggregates Measurement
FACILITATOR: Shelly Ji, Janssen R&D, LLC
SCRIBE: Chris Broomell, Takeda Pharmaceutical Company Limited

To view the table abstract and discussion notes, click here.

 

Table 35: ADCs: mAb or DS for Characterization and Control
FACILITATORS: Justin Sperry, Pfizer, Inc.
SCRIBES: Scott Berger, Waters Corporation

To view the table abstract and discussion notes, click here.

 

Table 36: Lean Control Systems for Biotech Products
FACILITATOR: Ruth Cordoba, MedImmune, A member of the AstraZeneca Group
SCRIBE: Xiao-Ping Dai, Celgene Corporation

To view the table abstract and discussion notes, click here.

 

Table 37: Design of Stability Studies for Biotechnology Product Development and Lifecycle Management – A New USP Chapter
FACILITATOR: Bharat Dixit, Finch Therapeutics
SCRIBE: Mimi Roy, BioMarin Pharmaceutical, Inc.

To view the table abstract and discussion notes, click here.

 

Table 38: Risk Assessments to Address Differing Global Requirements
FACILITATOR: Annie Sturgess, Bristol-Myers Squibb Company
SCRIBE: Patsy Lewis, Seattle Genetics, Inc.

To view the table abstract, click here.

 

Table 39: Data Integrity: Harmonizing Regulatory Requirements with Current and Emerging Technology
FACILITATOR: Christina Vessely, Biologics Consulting
SCRIBE: Carmilia Jimenez Ramirez, Gilead Sciences Inc.

To view the table abstract and discussion notes, click here.

 

Table 40: Clinical Support of Specifications for Vaccines
FACILITATOR: Mark Schenerman, CMC Biotech-MAS Consulting
SCRIBE: Bill Egan, GlaxoSmithKline

To view the table abstract and discussion notes, click here.

 

Table 41: Low Endotoxin Recovery
FACILITATOR: Ned Mozier, Pfizer, Inc
SCRIBE: Fadi Hakki, MedImmune, A member of the AstraZeneca Group

To view the table abstract, click here.

 

Table 42: Data Management in the 21st Century
FACILITATOR: Joe Shambaugh, Genedata Inc.
SCRIBE: Linda Narhi, Amgen Inc.

To view the table abstract and discussion notes, click here. 

 

Table 43: Use of Crystal Structure-modelling Approach for CQA Assessment, Bioassay Design and Troubleshooting
FACILITATOR: Margaret Ricci, Amgen Inc.
SCRIBE: Mellisa Ly, Pfizer, Inc.

To view the table abstract and discussion notes, click here.

 

Table 44: Quality or Regulatory Submission: New Items in  Regulatory Filings?
FACILITATOR: Roman Drews, Daiichi Sankyo. Co., Ltd
SCRIBE: Carol Krantz, Seattle Genetics, Inc.

To view the table abstract and discussion notes, click here.

 

Table 45: Opportunities and Roadblocks to Global Access to Biopharmaceuticals
FACILITATOR: Helena Madden, Biogen
SCRIBE: Lesley Redfern, AbbVie, Inc.

To view the table abstract and discussion notes, click here.

 

Table 46: Combination Products – A Risk-Based Approach to Implement Control Strategy
FACILITATOR: Vickie Frydenlund, Genentech, a Member of the Roche Group
SCRIBE: Melissa Thompson, Pfizer, Inc.

To view the table abstract and discussion notesclick here.

 

Table 47: How will Global Isolationism Affect the Biopharmaceutical Industry
FACILITATOR: Jason Wood, Bruker Corporation
SCRIBE: Julia O’Neill, Tunnell Consulting

To view the table abstract, click here.

 

Table 48: ICH Guidelines for UV Exposure during Photostability Studies
FACILITATOR: Gregory Gallegos, Genentech, a Member of the Roche Group
SCRIBE: James Carroll, Pfizer, Inc.

To view the table abstract and discussion notes, click here.

 

Table 49: Global Strategies for Implementing QC Automation Post Approval
FACILITATOR: Cindy Wu, Genentech, a Member of the Roche Group
SCRIBE: Heather Hughes, Sanofi

To view the table abstract, click here.

 

Table 50: Pool for Tox…Pool for Ph1 GMP?
FACILITATOR: Varnika Roy, GlaxoSmithKline
SCRIBE: Gerry DiDonato, Bristol-Myers Squibb Company

To view the table abstract and discussion notes, click here.

 

    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

more Calendar

1/28/2019 » 1/31/2019
CMC Strategy Forum and WCBP 2019

1/29/2019 » 1/31/2019
WCBP 2019 Live Stream

3/12/2019 » 3/13/2019
CMC Strategy Forum Latin America 2019

Featured Members
William Weiss, Eli Lilly and CompanyFind out more about Will in this month's Member Spotlight!

Membership Software Powered by YourMembership  ::  Legal